242 related articles for article (PubMed ID: 36618908)
1. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience.
Giudice V; Serio B; Ferrara I; Manzo P; Gorrese M; Pepe R; Bertolini A; D'Alto F; Verdesca F; Langella M; Filippelli A; Selleri C
Front Pharmacol; 2022; 13():1052060. PubMed ID: 36618908
[TBL] [Abstract][Full Text] [Related]
2. 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center study.
Mei C; Ye L; Ren Y; Zhou X; Ma L; Xu G; Xu W; Lu C; Yang H; Luo Y; Jiang L; Lang W; Zhu H; Jin J; Tong H
Hematol Oncol; 2023 Aug; 41(3):546-554. PubMed ID: 36516239
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
El-Cheikh J; Bidaoui G; Saleh M; Moukalled N; Abou Dalle I; Bazarbachi A
Clin Hematol Int; 2023 Jun; 5(2-3):143-154. PubMed ID: 37071328
[TBL] [Abstract][Full Text] [Related]
4. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
5. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
8.
Watts J; Lin TL; Mims A; Patel P; Lee C; Shahidzadeh A; Shami P; Cull E; Cogle CR; Wang E; Uckun FM
Front Oncol; 2021; 11():806243. PubMed ID: 35096610
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
Báez-Gutiérrez N; Rodríguez-Ramallo H; Moreno MA; Arboli ER; Abdel-Kader Martín L
Ther Adv Hematol; 2021; 12():20406207211040335. PubMed ID: 34471510
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
[No Abstract] [Full Text] [Related]
11. Venetoclax, a new player in the treatment of children with high-risk myeloid malignancies?
Masetti R; Baccelli F; Leardini D; Locatelli F
Blood Adv; 2024 May; ():. PubMed ID: 38701350
[TBL] [Abstract][Full Text] [Related]
12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi A; Ediriwickrema A; Dutta R; Patel SA; Shomali W; Medeiros B; Iberri D; Gotlib J; Mannis G; Greenberg P; Majeti R; Zhang T
Leuk Lymphoma; 2020 Nov; 61(11):2700-2707. PubMed ID: 32543932
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.
Chatzikalil E; Roka K; Diamantopoulos PT; Rigatou E; Avgerinou G; Kattamis A; Solomou EE
J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610812
[TBL] [Abstract][Full Text] [Related]
15. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
16. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center.
Tenold ME; Moskoff BN; Benjamin DJ; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
Front Oncol; 2021; 11():649209. PubMed ID: 33777810
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia.
Wang W; Luo Q; Chen Q; Pang A; Fang K
Evid Based Complement Alternat Med; 2022; 2022():8691835. PubMed ID: 36276872
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country.
Mirgh S; Sharma A; Shaikh MRMA; Kadian K; Agrawal N; Khushoo V; Mehta P; Ahmed R; Bhurani D
Am J Blood Res; 2021; 11(3):290-302. PubMed ID: 34322294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]